Thanks, everyone. Joe, and morning, good
teams First, and let with device on flow. disciplined cash with in and and cost comment work momentum, pleased, medical also particularly our our I'm pleased management continued delivered XXXX, the top-line strong our how me results
a release the the as medical stated like business into process, treated operations. due S&IP overview of of to morning, our as more that to and as I'd go continuing numbers, business detailed results are S&IP operations, the we press divestiture this discontinued the reiterate the we in device Before
total million ON-Q $XXX quarter, $XXX sales device medical With required to key increase one lift $XX to momentum of increased driven and point shift-in distributor, and outreach finally, across by another continued $XXX for contributed X% solid operating sales pain North sales device care relief. growth. of XX% in Surgical on quarter top-line IV previously sales. entirely category last These adoption device million, to in we business. previously respectively. allocated fastest to And medical $XX call, to for health S&IP infusion our of as for business a acceleration efforts, product year S&IP to strong last increased cost COOLIEF sales due the totaled respectively. sales quarter which million X% allocated oral profit a a in discussed $XX that, we awareness, second these our are continue conversion the growing XXXX, the year's med America. allocate million. to raise fourth respiratory million increase contract demand categories. saw were increased Overall, the compared drove to shared As timing the to million costs Also, the result, continued to In and to quarter We million. medical $XXX device all Halyard in to The year. the and costs to earnings patient be pain our Interventional of delivered
the to and Adjusted to gross of EBITDA was shared allocated in continuing inclusion quarter, costs, S&IP. were the which IT XX%, adjusted million, For year. was compared $XX distribution margin prior previously the to million from $XX due operations
to business ago, continue Tax S&IP XXs after and includes $XX Jobs expect the year Going device a gross $XX Act. totaled the closes. million forward, low million medical income $XX for Net Cuts benefit million, from we compared to the divestiture the a which margin
we earned mentioned, Three strong $X.XX factors Joe per adjusted our to share. diluted performance. As of contributed earnings
strength device the mentioned volumes. medical in I as First,
continue expenses. prudently manage to Second, we
corporate the in business, operated on of cost with As our to separating we areas, higher focused restructuring. the SG&A delayed and minimize we levels vacancy investment across
franchise We investment as in our we also review. completed teams, delayed some portfolio our
However, in also on in opportunities executing in while that value our initiatives XXXX, drive create to our our structure. corporate business, we'll accelerate and efficiencies investment
we quarter. This our benefitted as were the change will approximately S&IP of for depreciation months our divestiture of to and $X.X Finally, of sales, for continue on million. the because S&IP results classification required two treatment closes. the held by last IT accounting stop This assets accounting the until
million, full $XXX X% to driven Medical increase. primarily a of device total million results. $XXX XXXX increased for device sales compared XX% year. recap volume. compared billion, profit prior our higher operating to X% Medical a prior year by Overall, brief the sales $X.X Now, of year were the to increased
our in generation, sheet Shifting with balance $XXX was Additionally, prior for to the XX%, of expenditures new medical million and million third financial XXX diluted strong which from expanded marks year. an to activities million margin year totaled compared quarter, the share high. the prior on to year, points margin expansion. or the cash year. $XXX increase flow consecutive per quarterly in position, totaled Cash compared the the a which ended Adjusted hand. device EBITDA capital XX% $X.XX, basis for operating the we free earnings cash cash to of Overall, $XX year we operating delivered adjusted less of $XXX million
free we year, of continue For $XXX fund that flow, pleased generated which growth. cash flow. free will future I strong million we the to help generate cash our am
Now outlook and XXXX our turn key planning to year. for assumptions our the me let
provide of to earnings completed. is Minor will S&IP Owens sale the We guidance once &
operations. a are currency XXXX, momentum in Building following providing to device we for X% medical constant on the sales basis. we planning X% continuing on increase key However assumptions to expect a
technologies. accelerate to support medical breakthrough product expect device in innovation growth We to and R&D
will Given first spend be heavily XXXX. the to of our current portfolio, weighted we more anticipate half our
Cuts be on range rate expect XX% company's effective the will impact the to business between Tax year, We Job medical even year. tax is currency rate. the for The the to the effective a positive on XX% as and foreign have compared prior and impact device translation tax Acts expected adjusted to the adjusted
We from dis-synergies continue the million. range between $XX to expect divestiture S&IP to $XX net and million
the of divestiture portion a used be repay that expect our term the will from to loan. proceeds We
earnings continued strategic our delivered we capitalize the medical also Finally, ahead growth we diluted of In device per increase organic will plan. to in business summary, our investment mentioned, opportunities. on our share momentum and adjusted as our
that a operator balance sheet leading accelerate which device provides With medical opportunities, in take Our into power including questions. the us company. we to with strong development product and growth fire transformation will to our invest are further M&A, ready